The synergistic inhibition of atherogenesis in apoE−/− mice between pravastatin and the sPLA2 inhibitor varespladib (A-002)
Open Access
- 1 April 2009
- journal article
- Published by Elsevier BV in Journal of Lipid Research
- Vol. 50 (4), 623-629
- https://doi.org/10.1194/jlr.m800361-jlr200
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5 , shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS studyHuman Molecular Genetics, 2007
- Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient micePharmacological Research, 2007
- Circulating Secretory Phospholipase A2 Activity and Risk of Incident Coronary Events in Healthy Men and WomenArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Granulocyte Macrophage Colony-Stimulating Factor Regulates Dendritic Cell Content of Atherosclerotic LesionsArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Secretory Phospholipase A2Group VArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stressJournal of Lipid Research, 2005
- Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen depositionJournal of Lipid Research, 2005
- The paraoxonase gene family and atherosclerosisFree Radical Biology & Medicine, 2005
- Group IIA Phospholipase A2 Mediates Lung Injury in Intestinal Ischemia–ReperfusionAnnals of Surgery, 2000
- Role of Group II Secretory Phospholipase A2in AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 1999